Progen Pharmaceuticals
FAQ
Progen Pharmaceuticals

2008 ASX Announcements

2010
2009
2008 2007

2006

31 December 2008
Progen and Avexa Merger Update

22 December 2008
Webcast: Progen and Avexa to Merge

22 December 2008
Merger of Progen and Avexa Presentation

22 December 2008
Progen and Avexa to Merge

10 December 2008
Company Secretary Resigns

5 December 2008
Notice of General Meeting/Proxy Form

24 November 2008
Results of Meeting

24 November 2008
Chairman's Address to Shareholders

24 November 2008
CEO's AGM Address

24 November 2008
Dr Stanley Chang - Withdrawl of Director Nomination

17 November 2008
Further Details on Capital Return to Shareholders

17 November 2008
Sale of PharmaSynth

14 November 2008
Requisition of General Meeting

13 November 2008
Strategy Recommendations & Board Response

12 November 2008
Resignation of Vice President Clinical & Medical Affairs

10 November 2008
Requisition of a General Meeting

23 October 2008
Progen's Annual Report 2008

23 October 2008
Progen AGM Documentation 2008

9 September 2008
Progen Receives NASDAQ Deficiency Notice

4 September 2008
Appendix 3Z - Prof John Zalcberg

4 September 2008
Progen restructures following wind-down of PATHWAY


28 August 2008
Progen Pharmaceuticals Announces Fiscal 2008 Financial Results

28 August 2008
Preliminary Final Report 30 June 2008

22 August 2008
Progen Appoints Corporate Advisor

14 August 2008
Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG11047, In Combination

11 August 2008
Shareholder Mail-Out
Click here for a copy of the newsletter

6 August 2008
Appendix 3B - New Issue Announcement

23 July 2008
Progen Terminates PATHWAY trial & confirms focus on potential high value molecules and M&A

2 July 2008
Progen Spins-Out Manufacturing Business

2 June 2008
Vice President of Research and Development Resignation

30 May 2008
Progen Presents on Epigenetics Platform at AACR

27 May 2008
Progen Corporate Presentation

19 May 2008
Progen Response to Media Coverage

15 May 2008
Progen Resumes Phase 1 Development of Anti-Cancer Agent PG11047

14 April 2008
Progen Presents PG500 Series at AACR Annual Conference San Diego
Click here for a copy of the poster

10 April 2008
New Issue Announcement

3 April 2008
New Issue Announcement

31 March 2008
New Issue Announcement

27 March 2008
Progen Restructures Manufacturing and Drug Discovery Divisions

19 March 2008
Progen Market Update - Response to Media Coverage

13 March 2008
Confirmation of Option Exercise Price

11 March 2008
Progen Announces Commencement of Global Phase 3 Trial

4 March 2008
Initial Director's Interest Notice

4 March 2008
Progen Expands Board of Directors

18 February 2008
Progen Half Yearly Results

13 February 2008
Phase 2 Preliminary Prostate Data

7 February 2008
Progen Closes Acquisition of Cellgate Inc

5 February 2008
Progen's Acquisition of Cellgate Teleconference
Click here to listen

4 February 2008
Cellgate Acquisition Presentation to Accompany Investor Teleconference

4 February 2008
Investor Teleconference dial-in details

4 February 2008
Cellgate Acquisition

1 February 2008
Financial Update

Home Our Company Our Technology Our Pipeline Investor Centre